tbuckley/cabot-search huggingface dataset:
FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results.
Authors: Lucas Goldfarb, Boris Duchemann, Kader Chouahnia, Lea Gomez, Gabriel Pop, Laurent Zelek, Michael Soussan
Journal: Journal of Clinical Oncology (2017)

e20554 Background: Immunotherapy becomes a standard treatment in non-small-cell lung carcinoma (NSCLC), locally advanced or metastatic, after prior chemotherapy. Because of systemic involvement and heterogeneity of the tumoral disease, methods of assessment are complex and the role of PET-FDG is not well established. The objective of the present study is to describe the results of FDG-PET in the evaluation of patients with NSCLC treated with checkpoint inhibitor (OPDIVO®, Nivolumab) in our academic center. Methods: A retrospective analysis of FDG-PET’s data was performed in 16 patients (performance status: 1), with NSCLC (13 adenocarcinoma, 2 squamous cell carcinoma and 1 large cell neuroendocrine carcinoma) and progression after at least one line of treatment, and treated with Nivolumab. All patients had an FDG-PET before and at 2 months (M2) of treatment. Patients showing progression at M2 had a third PET at M3 to confirm disease progression. Disease responses were assessed according to PERCIST criteria. Patients were considered as responders to Nivolumab treatment, if the treatment was pursued at least 6 months, or as non-responders if the treatment was pursued less than 6 months. Pseudoprogression was defined as a disease progression at M2, which was not confirmed on FDG-PET control at M3. Results: Assessment by FDG-PET after 2 months of treatment showed 8/16 partial metabolic responses (PMR), 6/16 progressive diseases (PD), 1/16 stable disease (SD) and 1/16 complete metabolic response (CMR). Among the patients with PMR, SD or CMR at M2 (n = 10), 90% (9/10) were considered as responders and 10% (1/10) as non-responder. Nivolumab was discontinued in patients with PD. One patient showed a pseudo progression at M2 (PMR at M3), and was eventually classified as non-responder. Conclusions: These results show an association between the metabolic response at M2 and the continuation of the treatment with Nivolumab in NSCLC patients. 90% of patients with early metabolic response showed a sustained response with Nivolumab. FDG-PET could be helpful in the therapeutic strategy of these patients and deserves to be assessed in prospective trials including a cost/benefit evaluation.
Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: Phase III EPIC trial
Authors: E. Hutt, A. Da silva, D. Pannier, E. Bogart, F. El-Hajbi, S. Villet, S. Clisant, M-C. Le Deley, A. Adenis
Journal: Annals of Oncology (2017)
Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
Authors: D. Cortinovis, J. von Pawel, K. Syrigos, J. Mazieres, R. Dziadziuszko, L. Fehrenbacher, P. Conkling, J. Goldschmidt, C.A. Thomas, R. Bordoni, M. Kosty, F.S. Braiteh, P. He, M. Ballinger, M. Gandhi, H. Patel, D.R. Gandara
Journal: Annals of Oncology (2017)
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
Authors: D. Melisi, G. Piro, F. Simionato, C. Carbone, M. Frizziero, G. Malleo, S. Zanini, R. Casolino, R. Santoro, M.M. Mina, C. Zecchetto, V. Merz, A. Scarpa, C. Bassi, G. Tortora
Journal: Annals of Oncology (2017)
Exome sequencing of tumor samples from S1107 “Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma (pRCC)”
Authors: P. Twardowski, X. Wu, M. Plets, C. Tangen, E. Plimack, N. Agarwal, N.J. Vogelzang, J. Wang, S. Tao, I. Thomson, P. Lara
Journal: Annals of Oncology (2017)
IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
Authors: N. Girard, C. Audigier Valette, J. Cadranel, I. Monnet, J. Hureaux, W. HILGERS, E. Fauchon, E. Fabre, B. Besse, P. Brun, D. Coëtmeur, E. Quoix, P. Mourlanette, F. Barlesi, S. Bordenave-Caffre, T. Egenod, P. Missy, F. Morin, D. Moro-Sibilot, O. Molinier
Journal: Annals of Oncology (2017)
Met/Axl system as a dual target in the mesothelioma pathway and invasiveness
Authors: G. Viscardi, V. Ciaramella, C.M. Della Corte, F. Papaccio, G. Esposito, R. Di Liello, T. Troiani, M. Orditura, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2017)
HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients
Authors: A. Navarro, S. Santasusagna, N. Vinolas Segarra, J.J. Castellano, J. Moises, S. Morales, J. Canals, C. Muñoz, J. Ramírez, R.M. Marrades, L. Molins, M. Monzo
Journal: Annals of Oncology (2017)
Effect of exercise on muscle immune response and mitochondrial damage and their relationship with cancer-related fatigue: A URCC NCORP study.
Authors: Anita Roselyn Peoples, Luke Joseph Peppone, Po-Ju Lin, Calvin Cole, Charles E. Heckler, Michelle Christine Janelsins, Steven Rousey, Adedayo A. Onitilo, Marianne Melnik, Karen Michelle Mustian
Journal: Journal of Clinical Oncology (2017)

10119 Background: Chemotherapy (CT) via inflammation and oxidative stress can cause muscle inflammatory injury, mitochondrial damage, and cancer-related fatigue (CRF). Following muscle and mitochondrial damage, various cytoplasmic and mitochondrial components are released into circulation. HLA-DQB1 gene encodes a protein involved in the activation of immune response, and is not expressed in normal muscle cells but is up-regulated under highly inflammatory states. Mitochondrial gene MT-CO2 encodes subunit 2 of complex IV, which plays a critical role in energy metabolism and mitochondrial function. We investigated the (i) influence of an exercise intervention, Exercise for Cancer Patients (EXCAP), on gene expression levels of muscle immune response and mitochondrial damage and (ii) the relationships of these genes with CRF. Methods: In this nationwide, multicenter, phase III RCT conducted through the URCC NCORP Research Base, cancer patients (N = 350; mean age = 55.7) were randomized to 2 groups: (i) CT and (ii) CT plus a 6-week individualized, home-based, aerobic and resistance exercise program (EXCAP). Gene expression and CRF were assessed pre- and post-intervention from whole blood by qPCR and from patient-report by MFSI, respectively. Results: T-tests revealed significant upregulation of peripheral HLA-DQB1 and MT-CO2 mRNA following CT in controls (both p &lt; 0.00001) while there was less up-regulation in exercisers (both p≤0.005). ANCOVA showed a trend for significant differences between controls and exercisers for HLA-DQB1 (9.2% vs 5.4%; p = 0.059) and MT-CO2 (16.3% vs 12.7%; p = 0.061). Pearson correlations revealed that increases in HLA-DQB1 (r = 0.21; p = 0.051) and MT-CO2 (r = 0.19; p = 0.025) were significantly associated with concurrent increase in CRF in controls, but not in exercisers. Conclusions: CT alters muscle immune response and mitochondrial gene expression causing muscle and mitochondrial damage, which may be mediators for CRF. EXCAP is a promising intervention that may reduce both muscle and mitochondrial damage via its positive effects on HLA-DQB1 and MT-CO2. Funding: NCI UGCA189961, R25 CA102618. Clinical trial information: NCT00924651.
Death by Gun Violence—A Public Health Crisis
Authors: Howard Bauchner, Frederick P. Rivara, Robert O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, Jay F. Piccirillo, Rita F. Redberg, John S. Rhee, June K. Robinson
Journal: JAMA Dermatology (2017)

The shooting in Las Vegas, Nevada, that left 59 people dead, 10 times that number wounded, and thousands of people with the psychological distress from being present at the scene during and after the massacre has once again raised the issue of what we as a nation can and should do about guns.The solution lies in not just focusing on Las Vegas and the hundreds of other mass shootings that have occurred in the United States in the last 14 months, but rather to underscore that on average almost 100 people die each day in the United States from gun violence.The 36 252 deaths from firearms in the United States in 2015 1 exceeded the number of deaths from motor vehicle traffic crashes that year (36 161). 1 That same year, the US Centers for Disease Control and Prevention reported that 5 people died from terrorism.Since 1968, more individuals in the United States have died from gun violence than in battle during all the wars the country has fought since its inception. 2uns do not make individuals, their families, or homes safer and they result in far more deaths to loved ones than to an intruder intending to cause harm. 3Often forgotten is that 60.7% of the gun deaths in 2015 in the United States were suicides. 1Means used to attempt suicide matter; guns will result in suicidal deaths well over 90% of the time, whereas ingestion of pills or wrist cutting will be unsuccessful more than 90% of the time.The majority of people who try to commit suicide but survive the attempt will not go on to die from suicide 4 ; if the attempt is with a gun, there will be no second chance at life.The journals of the JAMA Network are dedicated to improving the health of people across the globe.We do so by addressing the most important public health problems harming people and publishing the best science that can be done.The journals have published important work on gun violence; in the past year this has included studies on differences in gun use during terrorist attacks in the United States compared with other countries, 5 the effect of exposure to gun violence in the media on children's interest in real guns,
Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors
Authors: F-H. Wang, C. Ren, Y. Zhang, S. Yao, H. Feng, H. Wu, H-F. Song, R. Zhang, X-L. Wei, X-J. Xia, Q. Zhao, J-P. Yun, B-Y. Zou, M. Qiu, Z-Q. Wang, Y-H. Li, R. Xu
Journal: Annals of Oncology (2017)
<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Takuya Osada, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, H. Kim Lyerly
Journal: Clinical Cancer Research (2017)

Purpose: Hsp90, a chaperone to numerous molecular pathways in malignant cells, is elevated in aggressive breast cancers. We hypothesized that identifying breast cells with elevated Hsp90 activity in situ could result in early detection of aggressive breast cancers.Experimental Design: We exploited the uptake of an Hsp90 inhibitor by malignant cells to create an imaging probe (HS131) of Hsp90 activity by linking it to a near-infrared (nIR) dye. HS131 uptake into cells correlated with cell membrane expression of Hsp90 and was used to image molecular subtypes of murine and human breast cancers in vitro and in murine models.Results: HS131 imaging was both sensitive and specific in detecting the murine 4T1 breast cancer cell line, as well as subclones with differing metastatic potential. Highly metastatic subclones (4T07) had high HS131 uptake, but subclones with lower metastatic potential (67NR, 168FARN) had low HS131 uptake. We generated isogenic cell lines to demonstrate that overexpression of a variety of specific oncogenes resulted in high HS131 uptake and retention. Finally, we demonstrated that HS131 could be used to detect spontaneous tumors in MMTV-neu mice, as well as primary and metastatic human breast cancer xenografts. HS131 could image invasive lobular breast cancer, a histologic subtype of breast cancer which is often undetectable by mammography.Conclusions: An HSP90-targeting nIR probe is sensitive and specific in imaging all molecular subtypes of murine and human breast cancer, with higher uptake in aggressive and highly metastatic clones. Clinical studies with Hsp90-targeting nIR probes will be initiated shortly. Clin Cancer Res; 23(24); 7531-42. ©2017 AACR.
Abstract 18461: Seasonal Variation of Pulmonary Hypertension Hospitalizations
Authors: Mohit Pahuja, Ronak G Soni, Aman Handa, Nirmanmoh Bhatia, Sahil Agrawal, Nasir Hussain, Dhara Patel, Sana Kamdar, Ananthram Kalya
Journal: Circulation (2016)

Background: Hospitalizations for pulmonary hypertension (PH) have been steadily rising over the past decade. Though previous studies have described seasonal variations for several cardiovascular di...
Le contrôle de la tuberculose en Lettonie : les programmes DOTS intégrés et DOTS-plus
Authors: V Leimane, J Leimans
Journal: Eurosurveillance (2006)

Entre 1991 et 1998, le nombre de patients atteints de tuberculose en Lettonie a augmente de 2,5 fois avec une hausse simultanee de la tuberculose resistante et multiresistante (TB-MR). 
Une analyse descriptive des divers services, activites et strategies des programmes de TB dont les DOTS (Directly Observed Therapy Short-course) pour la tuberculose et le traitement de la TB-MR a ete realisee. Les donnees du registre national de la tuberculose, de la surveillance de la resistance aux medicaments, et de la base de donnees sur la TB-MR ont ete utilisees. Le programme national de controle de la tuberculose (NTAP, Nacionālā Tuberkulozes Apkarosanas Programma), finance par l’Etat, base sur la strategie DOTS recommandee par l’OMS a ete mis en place en Lettonie en 1996. Ce programme incluait des tests tuberculiniques dans les prisons. Le traitement de la TB-MR avec des medicaments de deuxieme intention a debute en 1997. Les taux de guerison ont augmente de 59,5% en 1996 a 77,5% en 2003. Au cours de cette periode, plus de 200 patients par an ont entame un traitement TB-MR, avec un taux de guerisons passant de 66% a 73%. Pendant cette periode, le nombre de patients TB-MR a diminue de plus de la moitie. Les resultats des traitements, y compris de la TB multiresistante, ont atteint l’objectif OMS, avec des taux de guerison de 85% pour les nouveaux cas. Ces resultats demontrent que le traitement et le suivi de la TB-MR via une approche individualisee peuvent etre appliques efficacement dans le cadre d’un programme TB global a l’echelle nationale. Une telle approche permet de traiter efficacement un nombre important de patients atteints de TB-MR. 
Des methodes de diagnostic rapide associees a l’identification rapide des cas et a des mesures d’isolement et de controle de l’infection pourraient permettre une baisse de la transmission de la tuberculose et de la TB-MR dans les hopitaux et la communaute. Il est essentiel que la gestion de la TB-MR se conforme aux recommandations de l’OMS afin d’endiguer l’apparition de resistance aux antituberculeux utilises en premiere et deuxieme intention.
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
Authors: Nicole U Stoffel, Colin I Cercamondi, Gary Brittenham, Christophe Zeder, Anneke J Geurts-Moespot, Dorine W Swinkels, Diego Moretti, Michael B Zimmermann
Journal: The Lancet Haematology (2017)
Trichinellose associée au porc : l'émergence d'un nouveau mode de transmission ?
Authors: J C Desenclos
Journal: Eurosurveillance (1999)

Dans ce numero, Eurosurveillance publie un article portant sur deux epidemies de trichinellose - respectivement huit et 44 cas - survenues d'octobre a decembre 1998 en Allemagne dans l'etat de Rhenanie-du-Nord-Westphalie. Des enquetes epidemiologiques bien menees ont permis d'identifier les vehicules de l'infection : une viande de porc hachee commercialisee uniquement dans un supermarche dans le cas de l'epidemie la plus petite, et des saucisses fumees crues produites par une seule societe dans le cas de l'autre epidemie.
Dynamics of plasma cytokines in a patient with deficiency of interleukin-36 receptor antagonist successfully treated with anakinra
Authors: S. Podlipnik, D. Morgado-Carrasco, X. Fustà-Novell, A. Mensa-Vilaró, J.I. Arostegui, M. Alsina-Gibert, J.M. Mascaró Jr
Journal: British Journal of Dermatology (2017)

Generalized pustular psoriasis (GPP) is an autoinflammatory disease characterized by abrupt-onset episodes of erythematous skin plaques with countless pustules, fever, marked neutrophilia and increased acute phase reactants (APR).1 Loss-of-function mutations in the IL36RN gene, encoding for interleukin (IL)-36 receptor antagonist (IL-36Ra), have been described in a significant proportion of GPP patients.2,3 Previous studies have shown in vitro and ex vivo enhanced production of pro-inflammatory cytokines (IL-1, IL-6 and IL-8) and successful outcomes with anti-IL-1 drugs in patients carrying IL36RN mutations.1,2 However, little is known about the correlation of plasma cytokines, inflammatory markers and clinical follow-up, before and after treatment with anti-IL-1 drugs.

This article is protected by copyright. All rights reserved.
GW28-e0978 A study on the mechanism of the TGF-β in Ginsenoside Rb1 against the replicative senescence of endothelial cells
Authors: Bin Zhou, Dinghui Liu, Shujie Yu, Min Wang, Lin Wu, Yong Liu, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2017)
The Lower Seven-Eighths
Authors: Joseph Gascho
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 330: Glycogen Synthase Kinase-3a Negatively Regulates Fatty Acid Metabolism During Lipid-induced Insulin Resistance
Authors: Michinari Nakamura, Junichi Sadoshima
Journal: Circulation Research (2013)

Obesity and insulin resistance lead to ectopic lipid accumulation and impaired cardiac metabolism, resulting in cardiovascular diseases. Peroxisome proliferator-activated receptor α (PPARα) is highly expressed in the heart and serves as a key regulator of fatty acid metabolism. However, the underlying mechanisms responsible for the development of cardiac dysfunction in these pathologies are still poorly understood. GSK-3α was activated, as evidenced by a decrease in S21 phosphorylation, during insulin resistance with normoglycemia in the hearts of obese mice fed a high-fat diet and ob/ob mice. To evaluate the functional significance of GSK-3α upregulation with regard to metabolism, we applied 50 μM of BSA-conjugated palmitic acid to cardiomyocytes in vitro for three days. This intervention elicited ectopic lipid accumulation, as evaluated with Oil Red O staining, and a 2.0-fold activation of GSK-3α, similar to lipid-induced insulin resistance and dyslipidemia in the heart in vivo . In this condition, downregulation of GSK-3α with shRNA-GSK-3α in cardiomyocytes increased cell viability, ATP synthesis, and fatty acid oxidation, but not glycolysis. Downregulation of GSK-3α also increased the activity of PPRE-luciferase (1.5 fold, p&lt;0.05) and mRNA expression of genes involved in fatty acid metabolism in response to palmitic acid, including Acox1 and Cpt1b . Overexpression of GSK-3α induced a rightward shift of the dose response curve where the activity of the PPARα reporter was plotted against the dose of WY14643, a PPARα agonist. GSK-3α, but not GSK-3β, directly interacted with and phosphorylated PPARα in vitro . Collectively, these results suggest that GSK-3α negatively regulates ligand-dependent activity of PPARα through phosphorylation of PPARα, thereby inhibiting fatty acid metabolism during lipid-induced insulin resistance. GSK-3α may be a novel therapeutic target for metabolic disorders.
An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder
Authors: P.A. Ott, A. Naing, G. Ramaswamy, K. Margolin, M. Moles, R. Gaynor, M.J. Goldstein, S. Hu-Lieskovan
Journal: Annals of Oncology (2017)
Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland
Authors: C.M. Kelly, R. Feighery, J. McCaffrey, M. Higgins, M. Smith, S. O'Reilly, C. Murphy, A. Horgan, J. Walshe, R. McDermott, D. O'Donnell, P.G. Morris, M. Keane, M. Martin, K. Duffy, A. Mihai, J. Armstrong, E. Mulroe, V. Murphy, C. Kelly
Journal: Annals of Oncology (2017)
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer
Authors: L. Gerratana, D. Basile, S. Zago, M.G. Vitale, G. Pelizzari, M. Bonotto, C. Bozza, M. Bartoletti, V. Fanotto, C. Lisanti, M. Cinausero, S. Barban, M. Lera, I. Venuti, M. Mansutti, A.M. Minisini, G. Fasola, F. Curcio
Journal: Annals of Oncology (2017)
GW28-e1178 Ticagrelor Versus High-Dose (150-mg) Clopidogrel in stable coronary heart disease With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention --- A prospective, randomized, single-center, crossover Study
Authors: Zhenyang Liang, Haiping Wang, Yi Li, Jing Li, Xiaozeng Wang, Yaling Han, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Perspectives d’évolution de la politique vaccinale BCG en France
Authors: D Lévy-Bruhl
Journal: Eurosurveillance (2006)

La politique francaise de vaccination BCG reposait jusqu’a recemment sur la primo-vaccination des enfants, obligatoire avant l’entree en collectivite, et la revaccination des enfants tuberculino-negatifs. Une revision de cette politique a ete entreprise en France depuis quelques annees. Elle s’est concretisee par la suppression, en 2004, de toutes les revaccinations ainsi que des tests tuberculiniques post-vaccinaux de routine effectues en dehors du diagnostic d’une tuberculose infection ou maladie ou de la surveillance des professionnels des secteurs sanitaires et sociaux soumis a l’obligation vaccinale. Sur la base d’une evaluation de l’impact epidemiologique qu’auraient respectivement le ciblage de la vaccination sur les enfants les plus a risque et la suppression totale de la vaccination BCG, ainsi que sur l’appreciation de la balance benefice-risque de ces 2 options, le Conseil superieur d’hygiene publique de France (CSHPF) s’est prononce en faveur du principe de la vaccination ciblee des enfants. Cependant, il a pose, comme prealable a la mise en œuvre de cette strategie, le renforcement de la mise en œuvre des autres mesures de lutte contre la tuberculose susceptibles d’avoir un impact sur le risque d’infection de l’enfant. Cette reflexion est rendue plus complexe par la disparition, debut 2006, de la mutipuncuture, technique utilisee en France pour plus de 90 % des primo-vaccinations par le BCG.
Renal dysfunction predicts the presence and extent of coronary artery disease on coronary CT angiography
Authors: Márcio Sommer Bittencourt, Edward A Hulten, Suhny Abbara, Brian Ghoshhajra, Venkatesh L Murthy, Frank J Rybicki, Michael Steigner, Quynh A Truong, Thomas J Brady, Marcelo Di Carli, Udo Hoffmann, Ron Blankstein
Journal: Circulation (2012)

Apresentado no American Heart Association Scientific Sessions 2012, realizado de 3-7 de novembro de 2012 em Los Angeles, CA